By: IPP Bureau
Last updated : June 04, 2025 12:37 pm
his is the second license extension of a Nurix autoimmune disease program by Sanofi in the last 90 days
Nurix Therapeutics, a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation medicines, announced that Sanofi has exercised its option to exclusively license Nurix’s STAT6 program, including the drug development candidate NX-3911, an oral, highly selective STAT6 degrader. STAT6 (signal transducer and activator of transcription 6) plays a central role in type 2 inflammation, which drives diseases such as atopic dermatitis and asthma.
"Using our DEL-AI platform, we identified novel DEL-derived chemical matter from which we developed, together with Sanofi, a potential best-in-class STAT6 degrader, NX-3911, which achieves rapid and complete STAT6 degradation,” said Gwenn M. Hansen, Chief Scientific Officer, Nurix. “NX-3911 is a potent, selective, orally administered degrader of STAT6 that shows robust efficacy in multiple preclinical models of atopic dermatitis and asthma, demonstrating anti-inflammatory efficacy in animal models equivalent to a STAT6 gene knockout.”
"This is the second license extension of a Nurix autoimmune disease program by Sanofi in the last 90 days, highlighting the power of our proprietary DEL-AI drug discovery platform to fuel the discovery of novel medicines to a range of therapeutically important targets like STAT6,” said Arthur T. Sands, President and CEO, Nurix. “Notably, our STAT6 program also includes additional differentiated discovery-stage assets, which could represent an additional product opportunity within our Sanofi collaboration.”
Under the 2019 collaboration agreement, Nurix is deploying its proprietary DEL-AI drug discovery platform to identify novel agents that use E3 ligases to induce degradation of specified drug targets. Sanofi has an option to license drug candidates resulting from the work, and Nurix retains its option to co-develop and co-promote up to two future products in the United States after studies to assess dosing, efficacy, and safety that provide clinical proof of concept.